Elisa Luno
Overview
Explore the profile of Elisa Luno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Labrador J, Luno E, Vellenga E, Brunet S, Gonzalez-Campos J, Chillon M, et al.
Leuk Lymphoma
. 2018 Dec;
60(5):1146-1155.
PMID: 30526152
Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified....
2.
Schanz J, Sole F, Mallo M, Luno E, Cervera J, Granada I, et al.
Genes Chromosomes Cancer
. 2018 Sep;
57(11):547-556.
PMID: 30248204
The study analyzes the clonal architecture and the abnormalities involved in a series of 191 patients with myelodysplastic syndromes (MDS) and 2-3 clonal abnormalities. All patients were extracted from an...
3.
Itzykson R, Crouch S, Travaglino E, Smith A, Symeonidis A, Hellstrom-Lindberg E, et al.
Blood Adv
. 2018 Aug;
2(16):2079-2089.
PMID: 30126931
Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts...
4.
Diez-Campelo M, Lorenzo J, Itzykson R, Rojas S, Berthon C, Luno E, et al.
Br J Haematol
. 2018 Apr;
181(3):350-359.
PMID: 29611196
Treatment with azacitidine (AZA) has been suggested to be of benefit for higher-risk myelodysplastic syndrome (HR-MDS) patients with chromosome 7 abnormalities (Abn 7). This retrospective study of 235 HR-MDS patients...
5.
Stauder R, Yu G, Koinig K, Bagguley T, Fenaux P, Symeonidis A, et al.
Leukemia
. 2018 Mar;
32(6):1380-1392.
PMID: 29572506
In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL in lower-risk MDS remain rare....
6.
de Swart L, Smith A, Haase D, Fenaux P, Symeonidis A, cermak J, et al.
Leuk Res
. 2018 Feb;
67:21-26.
PMID: 29407183
Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients with MDS have a normal karyotype. Usually, 20-25 normal metaphases (nMP) are considered...
7.
Puente-Moncada N, Costales P, Antolin I, Nunez L, Oro P, Hermosilla M, et al.
Mol Cancer Ther
. 2018 Jan;
17(3):614-624.
PMID: 29339551
Internal tandem duplication (ITD) or tyrosine kinase domain mutations of FLT3 is the most frequent genetic alteration in acute myelogenous leukemia (AML) and are associated with poor disease outcome. Despite...
8.
Nomdedeu M, Pereira A, Calvo X, Colomer J, Sole F, Arias A, et al.
Leuk Res
. 2017 Nov;
63:85-89.
PMID: 29121539
Isolate loss of chromosome Y (-Y) in myelodysplastic syndromes (MDS) is associated to a better outcome but it is also well described as an age-related phenomenon. In this study we...
9.
Puiggros A, Collado R, Calasanz M, Ortega M, Ruiz-Xiville N, Rivas-Delgado A, et al.
Oncotarget
. 2017 Sep;
8(33):54297-54303.
PMID: 28903342
Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of...
10.
Collado R, Puiggros A, Lopez-Guerrero J, Calasanz M, Larrayoz M, Ivars D, et al.
Cancer Lett
. 2017 Sep;
409:42-48.
PMID: 28888994
Although i(17q) [i(17q)] is frequently detected in hematological malignancies, few studies have assessed its clinical role in chronic lymphocytic leukemia (CLL). We recruited a cohort of 22 CLL patients with...